sinc
cluster
unknown
pneumonia
patient
found
decemb
wuhan
china
new
coronaviru
cov
temporarili
name
novel
coronaviru
world
health
organ
januari
suddenli
came
sight
viru
subsequ
renam
sever
acut
respiratori
syndrom
coronaviru
diseas
caus
name
coronaviru
diseas
covid
februari
patient
confirm
posit
nucleic
acid
test
china
countri
caus
death
due
acut
respiratori
failur
relat
complic
addit
suspect
infect
peopl
isol
wait
test
januari
announc
outbreak
china
public
health
emerg
intern
concern
patient
suffer
sever
acut
respiratori
syndrom
sar
due
coronaviru
virusrel
death
report
sinc
septemb
laboratoryconfirm
case
infect
middl
east
respiratori
syndrom
coronaviru
merscov
virusrel
death
report
emerg
infecti
diseas
lead
global
spread
caus
transfus
medicin
review
xxx
xxxx
xxx
china
prior
outbreak
emerg
infect
unfavor
impact
blood
suppli
howev
consider
must
also
given
safeti
transfus
recipi
even
emerg
infect
respiratori
diseas
previou
studi
indic
viral
rna
could
detect
plasma
serum
patient
infect
sarscov
merscov
differ
period
onset
symptom
howev
detect
viral
rna
polymeras
chain
reaction
pcr
equival
detect
intact
infecti
viru
although
note
case
sarscov
report
due
transfus
blood
product
still
theoret
risk
transmiss
sarscov
transfus
asymptomat
infect
found
among
case
blood
safeti
worthi
consider
review
detail
current
evid
understand
transmiss
sarscov
merscov
via
transfus
februari
discuss
pathogen
inactiv
method
coronavirus
largest
known
rna
virus
cov
divid
four
genera
among
abl
infect
mammal
wherea
two
genera
infect
bird
could
also
infect
mammal
far
seven
coronavirus
found
infect
human
caus
respiratori
diseas
four
seven
common
human
cov
hcov
usual
lead
common
selflimit
upper
respiratori
diseas
virus
occasion
caus
seriou
diseas
young
elderli
immunocompromis
individu
first
two
hcov
known
sinc
emerg
sar
novel
came
attent
subsequ
identifi
respect
merscov
isol
similar
sarscovboth
infect
lower
respiratori
tract
usual
caus
sever
respiratori
syndrom
human
case
fatal
rate
respect
recent
isol
human
airway
epitheli
cell
character
nextgener
sequenc
januari
identifi
new
member
also
infect
lower
respiratori
tract
clinic
symptom
milder
sar
mer
accord
current
limit
evid
report
atyp
pneumonia
put
caus
sarscov
first
identifi
follow
outbreak
guangdong
provinc
china
novemb
infect
quickli
spread
beij
hong
kong
vietnam
singapor
canada
march
diseas
prove
highli
infecti
respiratori
droplet
main
rout
transmiss
infect
fece
also
play
import
role
cluster
outbreak
case
fortun
prove
sar
patient
infecti
period
incub
within
day
infect
usual
day
mani
studi
found
sarscov
rna
could
detect
plasma
sar
patient
even
though
respiratori
diseas
first
report
publish
april
indic
extrem
low
concentr
viral
rna
exist
plasma
sar
patient
acut
phase
ill
day
onset
symptom
viral
content
plasma
low
research
could
detect
sarscov
rna
use
nest
pcr
assay
establish
inhous
viral
load
copiesml
perform
ultracentrifug
ml
plasma
could
detect
viral
rna
plasma
collect
two
close
contact
although
sputum
one
posit
differ
pcr
assay
viral
load
sputum
high
copiesml
base
studi
inform
us
food
drug
administr
fda
draft
recommend
blood
safeti
point
theoret
risk
transmiss
sar
viru
transfus
blood
product
also
recommend
precautionari
principl
regard
deferr
blood
donat
individu
area
recent
local
transmiss
addit
blood
donor
report
collect
agenc
diagnos
suspect
confirm
sar
patient
within
month
follow
donat
instanc
effort
would
made
trace
recipi
recal
blood
product
transfus
later
two
studi
focus
new
pcr
method
detect
sarscov
rna
one
studi
base
serial
analysi
plasma
viral
rna
concentr
adult
sar
patient
quantit
reversetranscript
pcr
limit
detect
copiesml
studi
found
first
day
fever
onset
confirm
patient
detect
viral
rna
plasma
day
proport
fell
overal
patient
detect
viral
rna
first
week
ill
similar
first
studi
averag
viral
concentr
low
copiesml
patient
rel
mild
symptom
requir
intens
care
unit
admiss
hospit
pediatr
patient
children
viremia
median
concentr
plasma
copiesml
base
pcr
method
use
adult
sar
patient
final
grant
et
al
report
within
day
fever
onset
patient
detect
sarscov
rna
plasma
viral
load
level
rose
fast
maxim
viral
load
around
day
day
onset
fever
viral
load
quickli
decreas
find
show
viral
shed
plasma
common
peopl
clinic
ill
sar
viru
plasma
may
better
sampl
compar
nasal
throat
swab
detect
sensit
plasma
equival
nasopharyng
aspir
within
first
day
onset
fever
addit
research
found
lymphocyt
much
higher
concentr
sarscov
rna
plasma
whether
test
acut
phase
convalesc
phase
although
plasma
viral
rna
patient
acut
phase
convalesc
phase
detect
subsequ
shown
sarscov
could
infect
lymphocyt
also
replic
selflimit
manner
find
provid
evid
lymphocyt
might
one
target
sarscov
indic
potenti
transmiss
risk
blood
product
high
concentr
donor
lymphocyt
peripher
blood
stem
cell
bone
marrow
granulocyt
concentr
etc
although
find
provid
evid
sarscov
inde
exist
plasma
lymphocyt
sar
patient
nation
includ
local
transmiss
sar
organ
includ
american
associ
blood
bank
aabb
recommend
screen
donor
sarscov
rna
relat
antibodi
base
follow
fact
sar
patient
infecti
period
incub
time
incub
time
rel
short
almost
sarscovinfect
peopl
sever
symptom
asymptomat
carrier
found
data
show
viral
load
plasma
sar
patient
low
transfus
transmiss
case
report
far
studi
screen
blood
donat
sarscov
rna
fail
identifi
posit
howev
altern
view
express
research
hong
kong
found
test
plasma
healthi
blood
donor
nonpneumon
pediatr
inpati
collect
outbreak
sar
test
posit
igg
antibodi
sarscov
result
confirm
two
western
blot
assay
presenc
antibodi
impli
infecti
materi
nevertheless
hong
kong
among
worsthit
region
world
outbreak
sar
conclud
hong
kong
subclin
nonpneumon
sarscov
infect
exist
indic
potenti
transmiss
risk
sar
viru
via
blood
product
soon
afterward
four
differ
group
rais
question
object
hong
kong
studi
focus
specif
assay
repres
popul
provid
addit
inform
theoret
risk
sarscov
transmiss
blood
transfus
estim
shenzhen
guangdong
provinc
china
estim
use
data
shenzhen
hong
kong
taiwan
calcul
mean
risk
confid
interv
ci
per
million
maximum
risk
ci
per
million
april
mer
viru
first
identifi
man
acut
pneumonia
renal
failur
fatal
outcom
saudi
arabia
time
merscov
sixth
human
coronaviru
identifi
mer
highli
lethal
respiratori
diseas
higher
case
fatal
rate
sar
caus
larg
nosocomi
outbreak
jeddah
kingdom
saudi
arabia
republ
korea
studi
viral
load
differ
sampl
among
mer
patient
investig
found
nearli
half
serum
sampl
test
yield
viral
rna
signal
first
week
diagnosi
viral
load
rang
copiesml
howev
fail
isol
viru
sera
therefor
known
whether
live
mer
viru
serum
patient
blood
may
infecti
although
almost
mer
patient
sever
clinic
symptom
atyp
patient
found
outbreak
south
korea
one
individu
infect
merscov
confirm
realtim
reversetranscript
pcr
symptom
follow
day
howev
worthi
note
individu
test
immunocompromis
inpati
therefor
find
directli
relat
risk
among
blood
donor
document
aabb
note
popul
person
close
contact
confirm
case
camel
worker
visit
resid
middl
east
health
care
personnel
nosocomi
outbreak
increas
risk
merscov
infect
detect
viru
blood
rare
mer
viral
load
low
fda
recommend
deferr
criteria
similar
sar
epidem
day
last
exposur
day
arriv
unit
state
follow
travelresid
exposur
day
complet
symptom
resolut
cessat
treatment
decemb
unknown
pneumonia
rapidli
spread
wuhan
china
initi
case
relat
sourc
infect
seafood
wholesal
market
quickli
research
sequenc
identifi
new
genom
ident
previous
publish
bat
sarslik
cov
genom
distinct
human
sarscov
merscov
individu
usual
fever
lower
respiratori
tract
symptom
estim
incub
time
within
day
limit
data
shown
viral
rna
could
detect
plasma
serum
patient
first
patient
citi
wuhan
viremia
found
patient
median
pcr
cycl
threshold
valu
ci
suggest
low
rna
concentr
differ
found
intens
care
unit
patient
patient
mild
symptom
note
patient
posit
rna
fever
famili
cluster
report
shenzhen
china
found
serum
patient
one
famili
show
weak
posit
result
rna
child
confirm
asymptomat
carrier
viru
spread
world
report
vietnam
germani
unit
state
describ
clinic
symptom
diagnosi
treatment
one
controversi
report
suggest
transmiss
contact
asymptomat
carrier
germani
individu
china
attend
busi
meet
germani
infect
least
busi
partner
incub
period
report
suggest
contrast
sar
patient
might
infecti
asymptomat
incub
period
howev
report
author
directli
interview
chines
travel
later
found
symptomat
time
contact
moreov
research
detect
viral
rna
sampl
taken
index
patient
period
incub
januari
european
center
diseas
prevent
control
ecdc
aabb
publish
rapid
risk
assess
outbreak
blood
safeti
ecdc
impli
precautionari
deferr
donat
blood
cell
day
possibl
exposur
confirm
patient
anyon
return
wuhan
chinaappli
approach
use
sarscov
merscov
addit
recov
confirm
patient
defer
least
day
symptom
resolut
complet
therapi
aabb
updat
web
site
state
consid
concern
regard
blood
safeti
would
continu
close
monitor
outbreak
respiratori
ill
aabb
fda
center
diseas
control
prevent
current
requir
action
blood
collect
test
data
suggest
risk
transfus
transmiss
infect
continu
demand
urgent
attent
china
close
monitor
worldwid
follow
point
may
relev
consider
regard
transfus
organ
transplant
viral
rna
plasma
serum
could
detect
patient
first
day
onset
symptom
patient
especi
younger
adult
donat
blood
milder
symptom
older
adult
patient
fever
asymptomat
carrier
identifi
china
increas
possibl
patient
viru
carrier
could
donat
blood
rate
infect
patient
incub
period
remain
uncertain
data
viral
load
plasma
serum
lymphocyt
among
individu
incub
period
therefor
whether
risk
transfus
transmiss
higher
coronavirus
especi
endem
area
wuhan
china
explor
soon
possibl
still
need
care
assess
measur
regard
deferr
donor
screen
rna
test
virusrel
antibodi
use
pathogeninactiv
blood
product
coronavirus
envelop
positivesens
singlestrand
rna
virus
usual
coronavirus
vulner
acidph
basicph
heat
seem
stabl
infecti
titer
viru
show
signific
reduct
cycl
thaw
freez
outbreak
sar
mer
studi
investig
pathogen
inactivationreduct
technolog
prt
base
inhous
commerci
method
aim
decreas
complet
erad
potenti
risk
transmiss
coronavirus
via
blood
product
blood
deriv
studi
summar
tabl
gener
singl
prt
suitabl
blood
product
blood
compon
damag
prt
treatment
inhous
studi
method
inactiv
coronavirus
plasma
platelet
concentr
focus
mainli
heat
solventdeterg
sd
treatment
usual
minut
enough
reduct
sarscov
plasma
without
cell
inactiv
could
achiev
hour
plasma
product
studi
heat
minut
could
reduc
log
tcid
ml
mer
viru
heat
could
denatur
protein
blood
product
could
use
manufactur
plasmaderiv
product
addit
sarscov
found
sensit
solvent
deterg
tnbptriton
tnbptween
sodium
cholat
treatment
use
sd
produc
octapla
octapharma
viru
reduc
log
tcid
ml
illumin
differ
wavelength
also
influenc
activ
sar
mer
viru
blood
ultraviolet
uv
uvb
light
presenc
amotosalen
riboflavin
could
inactiv
pathogen
nucleic
acid
wherea
third
prt
method
use
uvc
light
commerci
system
could
reduc
activ
sar
mer
viru
plasma
platelet
concentr
differ
degre
methylen
blue
plu
visibl
light
also
abil
inactiv
coronavirus
plasma
cost
remain
major
administr
obstacl
prt
use
therefor
whether
prt
implement
respons
sever
preval
differ
region
actual
risk
transfus
transmiss
although
coronavirus
caus
primarili
mild
sever
respiratori
infect
potenti
transmiss
transfus
worthi
consider
china
blood
center
blood
bank
taken
follow
measur
current
outbreak
take
bodi
temperatur
blood
donat
addit
question
donor
screen
questionnair
regard
whether
donor
rel
relat
symptom
travel
area
local
transmiss
wuhan
hubei
provinc
within
day
donor
high
risk
call
back
blood
donor
ask
donor
famili
current
physic
condit
donat
recal
untransfus
blood
product
infect
donor
howev
given
differ
sarscov
merscov
known
prior
recommend
use
sar
mer
suffici
face
mani
unknown
care
monitor
studi
continu
stricter
measur
could
implement
necessari
viral
rna
virusrel
antibodi
screen
blood
donat
use
prt
region
know
wuhan
blood
center
blood
bank
hubei
provinc
start
test
rna
blood
donat
sinc
februari
meanwhil
coronavirus
rna
could
detect
plasma
lymphocyt
staff
blood
center
laboratori
improv
biosafeti
protect
epidem
come
month
provid
enorm
amount
new
inform
allow
us
make
decis
regard
new
viru
public
safeti
research
receiv
specif
grant
fund
agenc
public
commerci
notfor
profit
sector
none
mb
intercal
nucleic
acid
mediat
format
singlet
oxygen
upon
illumin
plasma
reduct
log
tcid
ml
plasma
reduct
log
tcid
ml
bsa
bovin
serum
albumin
dmem
dulbecco
modifi
eagl
medium
fb
fetal
bovin
serum
mb
methylen
blue
na
avail
pb
phosphatebuff
salin
pfu
plaqueform
unit
tnbp
trinbutyl
phosphat
